The antibody-drug conjugate (ADC) market is entering a rapid growth phase, and its expansion is creating increasingly complex requirements for pharmaceutical packaging, particularly in secondary and commercial supply chain operations. Once considered an experimental oncology approach, ADCs are now one of the fastest-growing segments in cancer therapeutics, with more than 23 approved products globally and over 400 clinical programmes in development.

According to industry data, ADC clinical activity is accelerating sharply, with 93 Phase III trials initiated in 2025 compared to 67 in 2024 and 31 in 2023. Market value is projected to grow from approximately $20 billion today to $60 billion by 2030, reflecting both increased approvals and broader therapeutic applications beyond oncology.

This expansion is reshaping not only drug development but also the packaging systems required to support safe, compliant and scalable distribution. ADCs combine biologic antibodies with highly potent small-molecule payloads, creating a dual-risk profile that demands advanced containment, strict environmental controls and highly validated packaging workflows.

Secondary packaging is no longer a support function in ADC supply chains — it is a critical component of product safety, stability and regulatory compliance.

As explained by industry specialists, secondary packaging must ensure protection against contamination and degradation while also enabling precise, compliant labelling and safe handling of hazardous materials. These requirements are particularly important given the cytotoxic nature of ADC payloads and the strict controls required throughout manufacturing and distribution.

Stability is another key concern. Many ADCs are sensitive to temperature, humidity and light exposure, meaning packaging systems must maintain controlled conditions across storage and transport. Any deviation can impact product integrity and patient safety, making validation and process control essential.

However, the commercial model for ADCs adds another layer of complexity. Many therapies launch with small, indication-specific patient populations and then expand into broader uses over time. This creates a high-mix, low-volume manufacturing environment where frequent changeovers, multiple SKUs and evolving labelling requirements are the norm.

• High containment requirements: safe handling of potent cytotoxic materials.
• Small batch production: frequent changeovers and evolving packaging configurations.
• Global scalability: rapid expansion across multiple markets and indications.

Contract development and manufacturing organisations (CDMOs) and contract packaging organisations (CPOs) are increasingly central to this ecosystem. These partners invest in specialised containment systems, operator safety protocols and controlled environments capable of managing ADC-specific risks.

Looking ahead, ADC packaging is expected to evolve alongside drug delivery innovation. Current formats typically include lyophilised powders in sterile vials with light-protective secondary packaging. However, future developments are likely to include prefilled syringes, ready-to-use presentations and integration with autoinjector or pen-based delivery systems.

These shifts will require closer alignment between pharmaceutical companies and packaging partners to ensure compatibility between drug-device combinations, as well as consistent performance across lifecycle stages from clinical development to commercial scale.

Sustainability is also emerging as a secondary but important consideration in ADC packaging strategies. Because these products require high-containment environments, sustainability improvements are less about material reduction and more focused on design optimisation and operational efficiency. This includes rightsizing packaging components, reducing non-essential materials and improving logistics efficiency through lighter configurations and optimised cold-chain systems.

Operational efficiency within packaging facilities is also a key focus area. High-containment environments are energy-intensive, making HVAC optimisation, digital monitoring and process efficiency critical levers for reducing environmental impact while maintaining compliance standards.

CDMOs such as Sharp are positioning themselves as integrated partners across the ADC lifecycle, supporting secondary packaging, cartoning, kitting, serialization, cold chain storage and global distribution. Early engagement in development is increasingly important to ensure scalability and regulatory readiness as therapies progress through clinical stages into global commercial launches.

As the ADC market continues to expand, packaging is becoming a strategic enabler of both clinical success and commercial scalability. Companies that can manage the dual challenge of high containment and high complexity will play a critical role in bringing next-generation oncology therapies to global markets safely and efficiently.

Image concept: sterile pharmaceutical packaging line handling ADC vials, high-containment isolators, cold-chain shipping boxes, and digital monitoring systems tracking temperature and compliance across global distribution.